|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Sun K, Zheng R, Zeng H, Zhang S,
Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality
in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N, Thomssen C and Gnant M: St.
Gallen 2013: Brief preliminary summary of the consensus discussion.
Breast Care (Basel). 8:102–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edenfield J, Schammel C, Collins J,
Schammel D and Edenfield WJ: Metaplastic breast cancer: Molecular
typing and identification of potential targeted therapies at a
single institution. Clin Breast Cancer. 17:e1–e10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S,
Zhu W, Guan X, Li C, Qian H, et al: Assessing tumor heterogeneity
using ctDNA to predict and monitor therapeutic response in
metastatic breast cancer. Int J Cancer. Jun 26–2019.(Epub ahead of
print). View Article : Google Scholar
|
|
6
|
Lee KL, Kuo YC, Ho YS and Huang YH:
Triple-negative breast cancer: Current understanding and future
therapeutic breakthrough targeting cancer stemness. Cancers.
11(pii): E13342019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma B, Varney ML, Saxena S, Wu L and
Singh RK: Induction of CXCR2 ligands, stem cell-like phenotype and
metastasis in chemotherapy-resistant breast cancer cells. Cancer
Lett. 372:192–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Y, Luo B, An Y, Sun H, Cai H and Sun
D: Systematic review and meta-analysis of the prognostic value of
CXCR2 in solid tumor patients. Oncotarget. 8:109740–109751. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murdoch C and Finn A: Chemokine receptors
and their role in inflammation and infectious diseases. Blood.
95:3032–3043. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang Y, Feng Y, Wu W, Chang C, Chen D,
Chen S and Zhen G: MicroRNA-218-5p plays a protective role in
eosinophilic airway inflammation via targeting δ-catenin, a novel
catenin in asthma. Clin Exp Allergy. Sep 12–2019.(Epub ahead of
print). View Article : Google Scholar
|
|
11
|
Wang X, Iyer A, Lyons AB, Körner H and Wei
W: Emerging roles for G-protein coupled receptors in development
and activation of macrophages. Front Immunol. 10:20312019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rollins BJ: Chemokines. Blood. 90:909–928.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Debnath B, Xu S, Grande F, Garofalo A and
Neamati N: Small molecule inhibitors of CXCR4. Theranostics.
3:47–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Hayer KM, Brady DC and Counter CM: ELR+
CXC chemokines and oncogenic Ras-mediated tumorigenesis.
Carcinogenesis. 30:1841–1847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lloyd A, Modi W, Sprenger H, Cevario S,
Oppenheim J and Kelvin D: Assignment of genes for interleukin-8
receptors (IL8R) A and B to human chromosome band 2q35. Cytogenet
Cell Genet. 63:238–240. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobilka BK: G protein coupled receptor
structure and activation. Biochim Biophys Acta. 1768:794–807. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prado GN, Suetomi K, Shumate D, Maxwell C,
Ravindran A, Rajarathnam K and Navarro J: Chemokine signaling
specificity: Essential role for the N-terminal domain of chemokine
receptors. Biochemistry. 46:8961–8968. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moussouras NA, Getschman AE, Lackner ER,
Veldkamp CT, Dwinell MB and Volkman BF: Differences in
sulfotyrosine binding amongst CXCR1 and CXCR2 chemokine ligands.
Int J Mol Sci. 18(pii): E18942017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng Y, Ma XL, Wei YQ and Wei XW:
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in
cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer.
1871:289–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahuja SK and Murphy PM: The CXC chemokines
growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma,
neutrophil-activating peptide-2, and epithelial cell-derived
neutrophil-activating peptide-78 are potent agonists for the type
B, but not the type A, human interleukin-8 receptor. J Biol Chem.
271:20545–20550. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Damaj BB, McColl SR, Mahana W, Crouch MF
and Naccache PH: Physical association of Gi2alpha with
interleukin-8 receptors. J Biol Chem. 271:12783–12789. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu D, LaRosa GJ and Simon MI: G
protein-coupled signal transduction pathways for interleukin-8.
Science. 261:101–103. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knall C, Young S, Nick JA, Buhl AM,
Worthen GS and Johnson GL: Interleukin-8 regulation of the
Ras/Raf/mitogen-activated protein kinase pathway in human
neutrophils. J Biol Chem. 271:2832–2838. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knall C, Worthen GS and Johnson GL:
Interleukin 8-stimulated phosphatidylinositol-3-kinase activity
regulates the migration of human neutrophils independent of
extracellular signal-regulated kinase and p38 mitogen-activated
protein kinases. Proc Natl Acad Sci USA. 94:3052–3057. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng GZ, Park S, Shu S, He L, Kong W,
Zhang W, Yuan Z, Wang LH and Cheng JQ: Advances of AKT pathway in
human oncogenesis and as a target for anti-cancer drug discovery.
Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoffmann E, Dittrich-Breiholz O, Holtmann
H and Kracht M: Multiple control of interleukin-8 gene expression.
J Leukoc Biol. 72:847–855. 2002.PubMed/NCBI
|
|
29
|
Tang H, Sun Y, Shi Z, Huang H, Fang Z,
Chen J, Xiu Q and Li B: YKL-40 induces IL-8 expression from
bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways,
causing bronchial smooth muscle proliferation and migration. J
Immunol. 190:438–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clapham DE: Calcium signaling. Cell.
80:259–268. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lang K, Niggemann B, Zanker KS and
Entschladen F: Signal processing in migrating T24 human bladder
carcinoma cells: Role of the autocrine interleukin-8 loop. Int J
Cancer. 99:673–680. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schraufstatter IU, Chung J and Burger M:
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac
signaling pathways. Am J Physiol Lung Cell Mol Physiol.
280:L1094–L1103. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cohen-Hillel E, Yron I, Meshel T, Soria G,
Attal H and Ben-Baruch A: CXCL8-induced FAK phosphorylation via
CXCR1 and CXCR2: Cytoskeleton- and integrin-related mechanisms
converge with FAK regulatory pathways in a receptor-specific
manner. Cytokine. 33:1–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Britschgi A, Andraos R, Brinkhaus H,
Klebba I, Romanet V, Müller U, Murakami M, Radimerski T and
Bentires-Alj M: JAK2/STAT5 inhibition circumvents resistance to
PI3K/mTOR blockade: A rationale for cotargeting these pathways in
metastatic breast cancer. Cancer Cell. 22:796–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hebert CA, Vitangcol RV and Baker JB:
Scanning mutagenesis of interleukin-8 identifies a cluster of
residues required for receptor binding. J Biol Chem.
266:18989–18994. 1991.PubMed/NCBI
|
|
38
|
Snoussi K, Mahfoudh W, Bouaouina N, Fekih
M, Khairi H, Helal AN and Chouchane L: Combined effects of IL-8 and
CXCR2 gene polymorphisms on breast cancer susceptibility and
aggressiveness. BMC Cancer. 10:2832010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu H, Lin F, Wang Z, Yang L, Meng J, Ou Z,
Shao Z, Di G and Yang G: CXCR2 promotes breast cancer metastasis
and chemoresistance via suppression of AKT1 and activation of COX2.
Cancer Lett. 412:69–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shao N, Chen LH, Ye RY, Lin Y and Wang SM:
The depletion of interleukin-8 causes cell cycle arrest and
increases the efficacy of docetaxel in breast cancer cells. Biochem
Biophys Res Commun. 431:535–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ruan JW, Liao YC, Lua I, Li MH, Hsu CY and
Chen JH: Human pituitary tumor-transforming gene 1 overexpression
reinforces oncogene-induced senescence through CXCR2/p21 signaling
in breast cancer cells. Breast Cancer Res. 14:R1062012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee YS, Choi I, Ning Y, Kim NY,
Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD,
et al: Interleukin-8 and its receptor CXCR2 in the tumour
microenvironment promote colon cancer growth, progression and
metastasis. Br J Cancer. 106:1833–1841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Desurmont T, Skrypek N, Duhamel A,
Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane
N, Hebbar M, et al: Overexpression of chemokine receptor CXCR2 and
ligand CXCL7 in liver metastases from colon cancer is correlated to
shorter disease-free and overall survival. Cancer Sci. 106:262–269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Katoh H, Wang D, Daikoku T, Sun H, Dey SK
and Dubois RN: CXCR2-expressing myeloid-derived suppressor cells
are essential to promote colitis-associated tumorigenesis. Cancer
Cell. 24:631–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH,
Wang Z, Huang XW, Fan J and Zhou J: Overexpression of CXCL5
mediates neutrophil infiltration and indicates poor prognosis for
hepatocellular carcinoma. Hepatology. 56:2242–2254. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sharma B, Nannuru KC, Varney ML and Singh
RK: Host Cxcr2-dependent regulation of mammary tumor growth and
metastasis. Clin Exp Metastasis. 32:65–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Singh S, Varney M and Singh RK: Host
CXCR2-dependent regulation of melanoma growth, angiogenesis and
experimental lung metastasis. Cancer Res. 69:411–415. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cardona AE, Sasse ME, Liu L, Cardona SM,
Mizutani M, Savarin C, Hu T and Ransohoff RM: Scavenging roles of
chemokine receptors: Chemokine receptor deficiency is associated
with increased levels of ligand in circulation and tissues. Blood.
112:256–263. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Stadtmann A and Zarbock A: CXCR2: From
bench to bedside. Front Immunol. 3:2632012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Addison CL, Daniel TO, Burdick MD, Liu H,
Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A and Strieter RM:
The CXC chemokine receptor 2, CXCR2, is the putative receptor for
ELR+ CXC chemokine-induced angiogenic activity. J Immunol.
165:5269–5277. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Caunt M, Hu L, Tang T, Brooks PC, Ibrahim
S and Karpatkin S: Growth-regulated oncogene is pivotal in
thrombin-induced angiogenesis. Cancer Res. 66:4125–4132. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Marjon PL, Bobrovnikova-Marjon EV and
Abcouwer SF: Expression of the pro-angiogenic factors vascular
endothelial growth factor and interleukin-8/CXCL8 by human breast
carcinomas is responsive to nutrient deprivation and endoplasmic
reticulum stress. Mol Cancer. 3:42004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Petreaca ML, Yao M, Liu Y, Defea K and
Martins-Green M: Transactivation of vascular endothelial growth
factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for
IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell.
18:5014–5023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Martin D, Galisteo R and Gutkind JS:
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF)
expression and the autocrine activation of VEGFR2 in endothelial
cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1)
complex. J Biol Chem. 284:6038–6042. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kyriakakis E, Cavallari M, Pfaff D, Fabbro
D, Mestan J, Philippova M, De Libero G, Erne P and Resink TJ:
IL-8-mediated angiogenic responses of endothelial cells to lipid
antigen activation of iNKT cells depend on EGFR transactivation. J
Leukoc Biol. 90:929–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Niu G and Chen X: Why integrin as a
primary target for imaging and therapy. Theranostics. 1:30–47.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lin Y, Huang R, Chen L, Li S, Shi Q,
Jordan C and Huang RP: Identification of interleukin-8 as estrogen
receptor-regulated factor involved in breast cancer invasion and
angiogenesis by protein arrays. Int J Cancer. 109:507–515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nannuru KC, Sharma B, Varney ML and Singh
RK: Role of chemokine receptor CXCR2 expression in mammary tumor
growth, angiogenesis and metastasis. J Carcinog. 10:402011.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Welch DR and Hurst DR: Defining the
hallmarks of metastasis. Cancer Res. 79:3011–3027. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
van der Horst G, Bos L and van der Pluijm
G: Epithelial plasticity, cancer stem cells, and the
tumor-supportive stroma in bladder carcinoma. Mol Cancer Res.
10:995–1009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
De Larco JE, Wuertz BR, Rosner KA,
Erickson SA, Gamache DE, Manivel JC and Furcht LT: A potential role
for interleukin-8 in the metastatic phenotype of breast carcinoma
cells. Am J Pathol. 158:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
De Larco JE, Wuertz BR, Yee D, Rickert BL
and Furcht LT: Atypical methylation of the interleukin-8 gene
correlates strongly with the metastatic potential of breast
carcinoma cells. Proc Natl Acad Sci USA. 100:13988–13993. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Singh B, Berry JA, Vincent LE and Lucci A:
Involvement of IL-8 in COX-2-mediated bone metastases from breast
cancer. J Surg Res. 134:44–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kamalakar A, Bendre MS, Washam CL, Fowler
TW, Carver A, Dilley JD, Bracey JW, Akel NS, Margulies AG, Skinner
RA, et al: Circulating interleukin-8 levels explain breast cancer
osteolysis in mice and humans. Bone. 61:176–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jin K, Pandey NB and Popel AS: Crosstalk
between stromal components and tumor cells of TNBC via secreted
factors enhances tumor growth and metastasis. Oncotarget.
8:60210–60222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Halpern JL, Kilbarger A and Lynch CC:
Mesenchymal stem cells promote mammary cancer cell migration in
vitro via the CXCR2 receptor. Cancer Lett. 308:91–99. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yu PF, Huang Y, Han YY, Lin LY, Sun WH,
Rabson AB, Wang Y and Shi YF: TNFα-activated mesenchymal stromal
cells promote breast cancer metastasis by recruiting
CXCR2+ neutrophils. Oncogene. 36:482–490. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Marquette C and Nabell L:
Chemotherapy-resistant metastatic breast cancer. Curr Treat Options
Oncol. 13:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen Y and Zhang Y: Application of the
CRISPR/Cas9 system to drug resistance in breast cancer. Adv Sci
(Weinh). 5:17009642018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sharma B, Nawandar DM, Nannuru KC, Varney
ML and Singh RK: Targeting CXCR2 enhances chemotherapeutic
response, inhibits mammary tumor growth, angiogenesis, and lung
metastasis. Mol Cancer Ther. 12:799–808. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q,
Zhu J, Chen JJ, Huang RC, Chen ZS and Huang RP: Enhanced
chemosensitization in multidrug-resistant human breast cancer cells
by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat.
135:737–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jia D, Li L, Andrew S, Allan D, Li X, Lee
J, Ji G, Yao Z, Gadde S, Figeys D and Wang L: An autocrine
inflammatory forward-feedback loop after chemotherapy withdrawal
facilitates the repopulation of drug-resistant breast cancer cells.
Cell Death Dis. 8:e29322017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Stassi G, Garofalo M, Zerilli M,
Ricci-Vitiani L, Zanca C, Todaro M, Aragona F, Limite G, Petrella G
and Condorelli G: PED mediates AKT-dependent chemoresistance in
human breast cancer cells. Cancer Res. 65:6668–6675. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Festuccia C, Gravina GL, D'Alessandro AM,
Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C and
Bologna M: Downmodulation of dimethyl transferase activity enhances
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis in prostate cancer cells. Int J Oncol. 33:381–388.
2008.PubMed/NCBI
|
|
80
|
Zanca C, Cozzolino F, Quintavalle C, Di
Costanzo S, Ricci-Vitiani L, Santoriello M, Monti M, Pucci P and
Condorelli G: PED interacts with Rac1 and regulates cell
migration/invasion processes in human non-small cell lung cancer
cells. J Cell Physiol. 225:63–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yang SX, Costantino JP, Kim C, Mamounas
EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S and Swain SM:
Akt phosphorylation at Ser473 predicts benefit of paclitaxel
chemotherapy in node-positive breast cancer. J Clin Oncol.
28:2974–2981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zatelli MC, Molé D, Tagliati F, Minoia M,
Ambrosio MR and Degli Uberti E: Cyclo-oxygenase 2 modulates
chemoresistance in breast cancer cells involving NF-kappaB. Cell
Oncol. 31:457–465. 2009.PubMed/NCBI
|
|
83
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
van Nijnatten TJA, Moossdorff M, de Munck
L, Goorts B, Vane MLG, Keymeulen KBMI, Beets-Tan RGH, Lobbes MBI
and Smidt ML: TNM classification and the need for revision of pN3a
breast cancer. Eur J Cancer. 79:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F,
Dutcher J, et al: Breast cancer cell lines contain functional
cancer stem cells with metastatic capacity and a distinct molecular
signature. Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chen L, Fan J, Chen H, Meng Z, Chen Z,
Wang P and Liu L: The IL-8/CXCR1 axis is associated with cancer
stem cell-like properties and correlates with clinical prognosis in
human pancreatic cancer cases. Sci Rep. 4:59112014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Magnifico A, Albano L, Campaner S, Delia
D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S and
Tagliabue E: Tumor-initiating cells of HER2-positive carcinoma cell
lines express the highest oncoprotein levels and are sensitive to
trastuzumab. Clin Cancer Res. 15:2010–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cameron D, Casey M, Press M, Lindquist D,
Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B,
Crown J, et al: A phase III randomized comparison of lapatinib plus
capecitabine versus capecitabine alone in women with advanced
breast cancer that has progressed on trastuzumab: Updated efficacy
and biomarker analyses. Breast Cancer Res Treat. 112:533–543. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fernando RI, Castillo MD, Litzinger M,
Hamilton DH and Palena C: IL-8 signaling plays a critical role in
the epithelial-mesenchymal transition of human carcinoma cells.
Cancer Res. 71:5296–5306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Singh JK, Farnie G, Bundred NJ, Simões BM,
Shergill A, Landberg G, Howell SJ and Clarke RB: Targeting CXCR1/2
significantly reduces breast cancer stem cell activity and
increases the efficacy of inhibiting HER2 via HER2-dependent and
-independent mechanisms. Clin Cancer Res. 19:643–656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Harrison H, Farnie G, Howell SJ, Rock RE,
Stylianou S, Brennan KR, Bundred NJ and Clarke RB: Regulation of
breast cancer stem cell activity by signaling through the Notch4
receptor. Cancer Res. 70:709–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Luo M, Fan H, Nagy T, Wei H, Wang C, Liu
S, Wicha MS and Guan JL: Mammary epithelial-specific ablation of
the focal adhesion kinase suppresses mammary tumorigenesis by
affecting mammary cancer stem/progenitor cells. Cancer Res.
69:466–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liu S, Ginestier C, Ou SJ, Clouthier SG,
Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, et
al: Breast cancer stem cells are regulated by mesenchymal stem
cells through cytokine networks. Cancer Res. 71:614–624. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li HJ, Reinhardt F, Herschman HR and
Weinberg RA: Cancer-stimulated mesenchymal stem cells create a
carcinoma stem cell niche via prostaglandin E2 signaling. Cancer
Discov. 2:840–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ginestier C, Liu S, Diebel ME, Korkaya H,
Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum
D, et al: CXCR1 blockade selectively targets human breast cancer
stem cells in vitro and in xenografts. J Clin Invest. 120:485–497.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang Y, Tu L, Du C, Xie X, Liu Y, Wang J,
Li Z, Jiang M, Cao D, Yan X and Luo F: CXCR2 is a novel cancer
stem-like cell marker for triple-negative breast cancer. Onco
Targets Ther. 11:5559–5567. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kumar S, Wilkes DW, Samuel N, Blanco MA,
Nayak A, Alicea-Torres K, Gluck C, Sinha S, Gabrilovich D and
Chakrabarti R: ΔNp63-driven recruitment of myeloid-derived
suppressor cells promotes metastasis in triple-negative breast
cancer. J Clin Invest. 128:5095–5109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Uddin MM, Zou Y, Sharma T, Gatla HR and
Vancurova I: Proteasome inhibition induces IKK-dependent
interleukin-8 expression in triple negative breast cancer cells:
Opportunity for combination therapy. PLoS One. 13:e02018582018.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Schott AF, Goldstein LJ, Cristofanilli M,
Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G and Wicha M:
Phase Ib pilot study to evaluate reparixin in combination with
weekly paclitaxel in patients with HER-2-negative metastatic breast
cancer. Clin Cancer Res. 23:5358–5365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Jones SA, Moser B and Thelen M: A
comparison of post-receptor signal transduction events in Jurkat
cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated
activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett. 364:211–214.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Xue MQ, Liu J, Sang JF, Su L and Yao YZ:
Expression characteristic of CXCR1 in different breast tissues and
the relevance between its expression and efficacy of neo-adjuvant
chemotherapy in breast cancer. Oncotarget. 8:48930–48937.
2017.PubMed/NCBI
|
|
102
|
Ruffini PA: The CXCL8-CXCR1/2 axis as a
Therapeutic target in breast cancer stem-like cells. Front Oncol.
9:402019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Murugan AK, Grieco M and Tsuchida N: RAS
mutations in human cancers: Roles in precision medicine. Semin
Cancer Biol. Jun 27–2019.(Epub ahead of print). View Article : Google Scholar
|
|
104
|
Kufareva I, Salanga CL and Handel TM:
Chemokine and chemokine receptor structure and interactions:
Implications for therapeutic strategies. Immunol Cell Biol.
93:372–383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ning Y, Labonte MJ, Zhang W, Bohanes PO,
Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli
Venkata KC, et al: The CXCR2 antagonist, SCH-527123, shows
antitumor activity and sensitizes cells to oxaliplatin in
preclinical colon cancer models. Mol Cancer Ther. 11:1353–1364.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Singh S, Sadanandam A, Nannuru KC, Varney
ML, Mayer-Ezell R, Bond R and Singh RK: Small-molecule antagonists
for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing
tumor cell proliferation, survival, and angiogenesis. Clin Cancer
Res. 15:2380–2386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liu X, Peng J, Sun W, Yang S, Deng G, Li
F, Cheng JW and Gordon JR: G31P, an antagonist against CXC
chemokine receptors 1 and 2, inhibits growth of human prostate
cancer cells in nude mice. Tohoku J Exp Med. 228:147–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Bieche I, Chavey C, Andrieu C, Busson M,
Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R
and Lazennec G: CXC chemokines located in the 4q21 region are
up-regulated in breast cancer. Endocr Relat Cancer. 14:1039–1052.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Varney ML, Singh S, Li A, Mayer-Ezell R,
Bond R and Singh RK: Small molecule antagonists for CXCR2 and CXCR1
inhibit human colon cancer liver metastases. Cancer Lett.
300:180–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Brandolini L, Cristiano L, Fidoamore A, De
Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque
B, Benedetti E, et al: Targeting CXCR1 on breast cancer stem cells:
Signaling pathways and clinical application modelling. Oncotarget.
6:43375–43394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Steele CW, Karim SA, Leach JDG, Bailey P,
Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z,
et al: CXCR2 inhibition profoundly suppresses metastases and
augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer
Cell. 29:832–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hirose K, Hakozaki M, Nyunoya Y, Kobayashi
Y, Matsushita K, Takenouchi T, Mikata A, Mukaida N and Matsushima
K: Chemokine gene transfection into tumour cells reduced
tumorigenicity in nude mice in association with neutrophilic
infiltration. Br J Cancer. 72:708–714. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Nair P, Gaga M, Zervas E, Alagha K,
Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J and Chanez P;
Study Investigators, : Safety and efficacy of a CXCR2 antagonist in
patients with severe asthma and sputum neutrophils: A randomized,
placebo-controlled clinical trial. Clin Exp Allergy. 42:1097–1103.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Allegretti M, Cesta MC, Garin A and
Proudfoot AE: Current status of chemokine receptor inhibitors in
development. Immunol Lett. 145:68–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Maroulakou IG, Oemler W, Naber SP and
Tsichlis PN: Akt1 ablation inhibits, whereas Akt2 ablation
accelerates, the development of mammary adenocarcinomas in mouse
mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T
transgenic mice. Cancer Res. 67:167–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu H, Radisky DC, Nelson CM, Zhang H,
Fata JE, Roth RA and Bissell MJ: Mechanism of Akt1 inhibition of
breast cancer cell invasion reveals a protumorigenic role for TSC2.
Proc Natl Acad Sci USA. 103:4134–4139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li B, Hou D, Guo H, Zhou H, Zhang S, Xu X,
Liu Q, Zhang X, Zou Y, Gong Y and Shao C: Resveratrol sequentially
induces replication and oxidative stresses to drive p53-CXCR2
mediated cellular senescence in cancer cells. Sci Rep. 7:2082017.
View Article : Google Scholar : PubMed/NCBI
|
